Skip to main content

HRTX

Stock

HRTX

Stock
Health Care
Biotechnology

Performance overview

HRTX Price
Price Chart

Forward-looking statistics

Beta
1.22
Risk
97.51%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.

Company info

SectorHealth Care
IndustryBiotechnology
Employees204
Market cap$542.4M

Fundamentals

Enterprise value$442.4M
Revenue$148.5M
Revenue per employee—
Profit margin-5.24%
Debt to equity-6.23

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.05
Dividend per share—
Revenue per share$0.97
Avg trading volume (30 day)$3M
Avg trading volume (10 day)$4M
Put-call ratio—

Macro factor sensitivity

Growth+7.0
Credit+3.1
Liquidity-3.1
Inflation+1.1
Commodities+2.1
Interest Rates-1.3

Valuation

Dividend yield0.00%
PEG Ratio—
Price to sales2.26
P/E Ratio178.00
Enterprise Value to Revenue2.98
Price to book-11.87

Upcoming events

Next earnings dayMay 6, 2025
Next dividend day—
Ex. dividend day—

News

Heron Therapeutics (HRTX) Q1 Earnings and Revenues Top Estimates

Heron Therapeutics (HRTX) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $0.02 per share a year ago.

Zacks Investment Research (May 6, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free